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A B S T R A C T
Background
In neovascular age-related macular degeneration (AMD) new vessels grow under the retina distorting vision and leading to scarring.
This is exacerbated if the blood vessels leak. Photodynamic therapy (PDT) has been investigated as a way to treat the neovascular
membranes without affecting the retina.
Objectives
The aim of this review was to examine the effects of PDT in the treatment of neovascular AMD.
Search methods
We searched CENTRAL (Issue 2, 2009), MEDLINE (1966 to April 2009) and EMBASE (1980 to April 2009). We contacted experts
in the field and searched the reference lists of relevant studies.
Selection criteria
We included randomised trials of PDT in people with choroidal neovascularisation due to AMD.
Data collection and analysis
Two authors independently extracted the data. Risk ratios were combined using a random-effects model after testing for heterogeneity.
Main results
Four trials (1429 participants) comparing PDT with verteporfin to PDT with 5% dextrose in water were included in this review.
Participants received on average five treatments over two years. The risk ratio of losing 3 or more lines of visual acuity at 24 months
comparing the intervention with the control group was 0.80 (95% confidence interval (CI) 0.73 to 0.88). The risk ratio of losing 6
or more lines of visual acuity at 24 months comparing the intervention with the control group was 0.66 (95% CI 0.56 to 0.83). The
results at 12 months were similar to those at 24 months. The most serious adverse outcome, severe visual acuity decrease within one
week of treatment, occurred in 11 per 1000 patients (95% CI 3 to 48). Infusion related back pain was experienced by 20 per 1000
(95% CI 6 to 70). Two further trials compared different treatment regimens: standard versus delayed light application; retreatment
every two months versus every three months. Neither trial demonstrated differences in effectiveness. The overall quality of the evidence
included in this review was considered to be high. Five out of the six trials were funded by the manufacturers of verteporfin.
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Authors’ conclusions
Photodynamic therapy in people with choroidal neovascularisation due to AMD is effective in preventing clinically significant visual loss
with a relative risk reduction of approximately 20%. Modified treatment regimens have not convincingly shown increased effectiveness.
There was no evidence on quality of life and little on cost.
P L A I N L A N G U A G E S U M M A R Y
Photodynamic therapy for treating age-related macular degeneration
Photodynamic therapy involves injecting a photosensitive chemical (verteporfin) into the blood stream then radiating light onto the
affected area of the retina as the chemical flows through the eye. The chemical is activated enough to treat neovascular or “wet” age-
related macular degeneration by sealing the new blood vessels at the back of the eye. This review includes four randomised trials
involving 1429 participants. All four trials compared verteporfin therapy to 5% dextrose water (placebo treatment). Photodynamic
therapy reduces the risk of vision loss caused by “wet” age-related macular degeneration. More people treated with verteporfin also
experienced improvements in vision compared to the placebo group, however, the absolute numbers experiencing vision improvement
after this treatment was low (80 per 1000). A small number of people may experience acute vision loss within one week after treatment
(in approximately 1 in 100 people) and infusion related back pain can occur (in approximately 1 in 50 people).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Photodynamic therapy with verteporfin compared to photodynamic therapy with 5% dextrose in water for neovascular age-related macular degeneration
Patient or population: patients with neovascular age-related macular degeneration
Settings: hospital or office
Intervention: photodynamic therapy with verteporfin
Comparison: photodynamic therapy with 5% dextrose in water
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
photodynamic therapy
with 5% dextrose in wa-
ter
photodynamic therapy
with verteporfin
Loss of 3 or more lines
(15 or more letters) vi-
sual acuity
ETDRS chart
Follow-up: 24 months
609 per 1000 487 per 1000
(445 to 536)
RR 0.8
(0.73 to 0.88)
1381
(4 studies)
⊕⊕⊕⊕
high
Loss of 6 or more lines
(30 or more letters) vi-
sual acuity
ETDRS chart
Follow-up: 24 months
333 per 1000 220 per 1000
(176 to 276)
RR 0.66
(0.53 to 0.83)
1381
(4 studies)
⊕⊕⊕⊕
high
Gain of 3 or more lines
(15 or more letters)
Follow-up: 24 months
36 per 1000 80 per 1000
(43 to 151)
RR 2.23
(1.19 to 4.19)
941
(3 studies)
⊕⊕⊕⊕
high
Adverse effects: acute
severe visual acuity de-
crease
Follow-up: 7 days
3 per 1000 11 per 1000
(3 to 48)
RR 3.75
(0.87 to 16.12)
1075
(3 studies)
⊕⊕⊕©
moderate1
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Adverse effects: infu-
sion-related back pain
2 per 1000 20 per 1000
(6 to 70)
RR 9.93
(2.82 to 35.02)
1439
(4 studies)
⊕⊕⊕⊕
high2
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Serious imprecision: confidence intervals include 1 (no effect).
2 Not downgraded for imprecision: confidence intervals wide however do not include 1 (no effect).
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B A C K G R O U N D
Description of the condition
Age-relatedmacular degeneration (AMD) is a disease affecting the
macula, the central area of the retina. The disease is defined as
degeneration of the macula in older people (aged over 50) with no
other apparent cause for the degeneration.
There are several signs in the retina that are associated with in-
creasing age and increased risk of developing AMD. These signs,
known as age-related maculopathy, include the presence of drusen
(yellow spots beneath the retina) and pigmentary disturbance. In
general age-related maculopathy is not associated with visual loss.
Some people with age-related maculopathy will go on to develop
AMD.
There are two main types of AMD. In geographic atrophy (dry)
AMD, the retinal pigment epithelium is lost completely in lo-
calised areas. In neovascular (wet) AMD, sub-retinal neovascular
membranes (new blood vessels) develop beneath the retina. These
are associated with scarring of the retina that affects vision. The
new vessels can leak causing haemorrhage that leads to larger scars
or macular oedema and significant loss of vision. This review was
concerned with treatment for neovascular AMD.
Sub-retinal neovascular membranes are defined as classic or oc-
cult according to their appearance on fluorescein angiography, in
which fluorescent dye is injected intravenously and photographed
as it passes through the blood vessels of the eye. Classic membranes
are clearly delineated and leak fluorescein uniformly. Occultmem-
branes are often hidden or their extent is hard to delineate, and
fluorescein leakage is patchy. It is thought that these two angio-
graphic patterns reflect the different extent to which the vessels
have penetrated the retinal pigment epithelium, occult vessels ly-
ing underneath the retinal pigment epithelium. Some lesions may
have both classic and occult components.
Description of the intervention
Trials have shown that early laser photocoagulation of classic ex-
trafoveal membranes (those not directly underneath the fovea at
the centre of the macula) could delay the loss of vision in a small
number of patients (MPS 1994). However, most patients present
with subfoveal membranes, and whilst photocoagulation can limit
the extent of the subsequent visual loss, it causes immediate loss of
central vision due to the concurrent destruction of the overlying
retina.
Photodynamic therapy, originally used in the treatment of cancer,
has been investigated as a way to treat the neovascular membranes
without affecting the retina. Photoreactive chemicals are injected
into the patient and irradiated with light as they pass through the
neovascular membranes.
How the intervention might work
When the chemicals are activated, they emit free radicals that seal
up the blood vessels. However, this light is not strong enough to
cause damage to the overlying retina.
Why it is important to do this review
It is important to do this review to obtain an overall estimate of the
effectiveness of this treatment and to assess any harmful effects.
O B J E C T I V E S
The aim of this review was to examine the effects of PDT in the
treatment of neovascular AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included trials in which participants were people with neovas-
cular AMD as defined by the study investigators.
Types of interventions
We included any study in which PDT was compared to another
treatment, placebo or no treatment.
Types of outcome measures
Primary outcomes
The primary outcome for this review was prevention of visual
loss. Any well-defined outcome based on visual acuity was used
depending on the way in which authors presented trial data. Other
validated measures of visual loss, such as contrast sensitivity, were
used where available.
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Secondary outcomes
The secondary outcomes for this review were:
• new vessel growth;
• quality of life measures - any validated measurement scale
which aims to measure the impact of visual function loss on
quality of life of participants;
• any adverse outcomes as reported in trials.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vision
Group Trials Register) (The Cochrane Library, Issue 2, 2009),
MEDLINE (January 1950 to April 2009) and EMBASE (January
1980 to April 2009). There were no language or date restrictions
in the search for trials. The electronic databases were last searched
on 23 April 2009.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2) andEMBASE (Appendix
3).
Searching other resources
We used the Science Citation Index to search for reports that
cited relevant study reports. We contacted experts in the field for
information about further trials and we searched the reference lists
of relevant studies for further trial reports.
Data collection and analysis
Selection of studies
Two authors independently scanned the titles and abstracts result-
ing from the electronic searches.We obtained full copies of all po-
tentially or definitely relevant articles. Two review authors assessed
the full copies according to the ’Criteria for considering studies
for this review’. Only articles meeting these criteria were assessed
for quality.
Data extraction and management
Two authors independently extracted data using a form developed
by the Cochrane Eyes and Vision Group (available from the edi-
torial base). We resolved discrepancies by discussion. Two review
authors independently entered data into RevMan and we checked
any inconsistencies between the two against the study report.
For updates in Revman 5 both authors extracted data indepen-
dently. Data were entered into Revman 5 by one author (RW) and
checked by another (JE).
Assessment of risk of bias in included studies
For the original review, two authors independently assessed study
quality according to methods set out in Section 6 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2006).
The authors were not masked to any trial details during the as-
sessment. Four parameters of quality were considered: allocation
concealment and method of allocation to treatment, masking of
providers and recipients of care, masking of outcome assessment,
and completeness of follow up. Each parameter of trial quality
was graded: A (adequate); B (unclear); C (inadequate). Disagree-
ment between the review authors on assessments was resolved by
discussion. We contacted the trial authors for clarification on any
parameter graded B and we excluded any trial scoring C on allo-
cation concealment.
For the update in 2009 we used the Cochrane Collaboration tool
for assessing the risk of bias (Higgins 2008).
Measures of treatment effect
Our measure of treatment effect is the risk ratio.
Unit of analysis issues
In all the included trials, people were randomised to treatment and
one study eye, that received treatment or placebo, was identified.
Dealing with missing data
Three out of the four trials contributing to themain analyses in this
review imputed missing data by using the “last observation carried
forward” method. This method can give unpredictable results and
is not underpinned by statistical theory (www.missingdata.org.uk,
accessed June 23rd 2009). This made it difficult for us to do any
further assessment of this issue.
Assessment of heterogeneity
We looked at the forest plots to see the extent to which the confi-
dence intervals of the individual studies overlapped. We also con-
sidered the Chi2 test for heterogeneity and I2 value.
Assessment of reporting biases
Currently there are not enough trials included in this review to
assess publication bias. We did an “outcome reporting grid” to
assess the extent to which selective outcome reporting might have
occurred.
Data synthesis
We pooled the data from the individual studies using a random-
effects model.
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Subgroup analysis and investigation of heterogeneity
We did not plan any subgroup analyses in the protocol for this re-
view.However, following on from the subgroup analyses presented
in TAP 1999, one key issue is whether the effect of treatment is
different depending on the type of choroidal neovascularisation
lesion (classic or occult).
Sensitivity analysis
In our protocol we planned to determine the effect of excluding
studies at high risk of bias. All studies included in this review were
considered to be at low risk of bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
Details of the original searches are found in Appendix 4.
For the current update the search was conducted in April 2009.
This search found 94 new references and identified one new trial
(Schmidt-Erfurth 2008) for inclusion in the review. One further
unpublished trial was identified by a colleague who noticed that its
results were available on the EuropeanMedicines Agency (EMEA)
website (VIO 2007).While trying to locate a current email address
for the investigators on PubMed we found the publication for this
study which was published in June 2009.
The VER 2004, Valio 2007 and Schmidt-Erfurth 2008 trials were
all trials comparing modifications of the TAP treatment protocol
to the standard and are included here for completeness. VER 2004
remains in ’Characteristics of studies awaiting classification’ until
we can retrieve and translate the trial report published in German
(Stur 2004). The gist of the findings of this study are available
from two published (not peer reviewed) abstracts fromAssociation
for Research in Vision and Ophthalmology meetings (Stur 2001
and Stur 2005).
Additional reports fromTAP 1999 and VIP 2001 trials were iden-
tified (Kaiser 2006; Pieramici 2006) and the report from Japan
2003 study was identified. This was an uncontrolled case series re-
port and therefore not included in the review except as a comment
on evidence of effectiveness of PDT in other populations. The
additional reports from TAP and VIP provide longer term out-
comes at five years for people with predominantly classic lesions
who remained in the studies (Kaiser 2006). These constitute a rel-
atively small proportion of the original study populations. There
is a report from the placebo arm of the VIP study reporting on
the natural history of untreated lesions (Pieramici 2006), occult
lesions which evolve into predominantly classic lesions. None of
these reports provide additional evidence of effectiveness of PDT
which could be included in the review.
Included studies
Below is a summary of the included studies. Details can be found
in the ’Characteristics of included studies’ table.
TAP 1999 was a multicentre study investigating the safety and
effectiveness of verteporfin (Visudyne; CIBA Vision Corp, USA).
It was conducted in 22 ophthalmology practices in Europe and
North America. Participants were people with subfoveal choroidal
neovascularisation (CNV) caused by age-related macular degener-
ation. The majority of participants were white (98%) with a mean
age of 75 years. TAP 1999 was originally devised as two concur-
rent trials in order to comply with regulatory agency requirements.
The study protocols were identical. Ten of the clinical centres were
assigned to study A and 12 to study B. As the results of the trials
were similar and the investigators analysed and presented the data
as one trial, we have also assessed it as one trial.
TheVIP 2001 studywas very similar to the TAP 1999 study. It was
conducted in 28 practices, most of whom had also participated
in TAP 1999. As for TAP 1999, the majority of participants were
white (98%) with a mean age of 75 years.
In both trials verteporfin (6 mg/m2 body surface area) was com-
pared to placebo (5% dextrose in water) administered via intra-
venous infusion of 30 ml over 10 minutes. This was followed after
15 minutes by application of 83 seconds of laser light at 689 nm
delivered 50 joules/cm² at an intensity of 600 mW/cm² using a
spot size with a diameter 1000 microns larger than the greatest
linear dimension of the CNV lesion.
Participants in TAP 1999 were reviewed every three months when
visual acuity wasmeasured and repeat fluorescein angiography per-
formed. If the trial surgeon judged a recurrence of the membrane
to be present or a persistence of the previous lesion, then repeat
treatment was undertaken. In the phase one and two studies it was
concluded that up to five treatments were necessary to stabilise the
situation (Miller 1999; Schmidt-Erfurth 1999). In the first year
a mean of 3.4 treatments were delivered to the treatment group
and 3.7 to the control group. In the second year a mean of 2.2
treatments were delivered to the treatment group and 2.8 to the
controls group.
Visual acuity was measured in VIP 2001 at 12 and 24 months.
The report of the study did not indicate the mean number of
treatments delivered for all participants. However, in the subgroup
with occult CNV (76% of all participants) 3.1 treatments were
given in the treatment group and 3.5 in the control group. In the
second year, 1.8 and 2.4 treatments were given in the verteporfin
and control groups respectively.
There are a total of 15 papers published on the TAP and VIP trials
which are summarised briefly (Table 1).
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The VIM 2005 trial randomised participants with minimally clas-
sic subfoveal choroidal neovascularisation due to age-related mac-
ular degeneration to verteporfin injections or placebo in a ratio 2:
1. All participants were also randomised to two intensities of light
illumination after verteporfin injection, either standard fluence
equivalent to 50 Joules/cm2 or reduced fluence of 25 Joules/cm2.
This was based on the idea that a less intense illuminationmay lead
to less tissue damage and as a consequence less inflammation and
potential sight loss following the treatments. The placebo treated
group received an average of three treatments while the verteporfin
treated SF group had an average of 2.9 and the RF group, 3.1
treatments in the first 12 months. In the second 12 month pe-
riod, some placebo treated participants received treatment with
verteporfin because their lesion converted from minimally classic
to predominantly classic. This was an ethical requirement of the
study design because PDT had been previously shown to be effec-
tive for predominantly classic lesions.
While engaged in the latest update (2009), a published report of
the VIO 2007 appeared. Though details of the study had been
posted on an EMEA website, we lacked the details of the study
methodology and there was no evidence of formal peer review.
With the details provided in the publication, it was clear to the
review authors that it should be included in the review. The trial
randomised more than 360 people with occult subretinal neo-
vascularisation to verteporfin or placebo (2:1 ratio) in 43 centres
across North America.
The report suggests a similar protocol to the VIP 2001 was used.
The Valio 2007 trial randomised 60 patients 1:1 to either Altered
Light treatment usingdelayed light afterVisudyne inOccult AMD
or the standard TAP 1999 protocol. There was no placebo arm.
The Schmidt-Erfurth 2008 trial randomised 203 patients with
predominantly classic choroidal neovascularization (CNV) due to
AMD. During the first six months of treatment, patients received
treatment either every two or threemonths. After sixmonths, both
groups underwent retreatment every three months for as long as
CNV activity was documented.
The VER 2004 trial had a similar design and randomised 320
people with predominantly classic CNV to early retreatment ev-
ery 1.5 months or every three months in the first six months of
treatment. This study is awaiting classification.
Risk of bias in included studies
Risk of Bias tables are now provided for all included studies. See
Figure 1 and Figure 2.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Both TAP 1999 and VIP 2001 were high quality studies with a
very similar study design.
Allocation of treatment group was by opaque serially-numbered
sealed envelopes and was stratified by clinical centre. The baseline
characteristics of the participants by treatment group were pub-
lished. The groups were well balanced with respect to a variety of
demographic and clinical variables. Only one eye per person was
treated.
Reasonable attempts weremade tomask the ophthalmologist, par-
ticipant, vision examiner and Photograph Reading Center per-
sonnel to the treatment assigned. As verteporfin and placebo were
different colours (green versus colourless), the solutions and the
intravenous tubing were covered with foil. The fundus appearance
does not change during treatment to indicate whether verteporfin
or placebo had been infused. There is no other physical evidence
of treatment as verteporfin dye is excreted in the faeces and does
not cause any colour change, and does not alter the colour of
the skin or urine. It was therefore unlikely that participants were
aware of their treatment status. In TAP 1999 the study investiga-
tors reported two instances where the participants were unmasked,
and four cases where the ophthalmologists were unmasked, having
noted a green solution.
Rates of follow up were high in both studies. In TAP 1999 94%
were seen at 12 months and 87% at 24 months. Follow up was
similar between the two treatment groups. The analysis was in-
tention-to-treat. Missing data were imputed using the last obser-
vation carry forward method. There were a number of subgroup
analyses. These were specified in principle in the protocol although
it is unclear if the specific details of the subgroups to be consid-
ered were specified a priori. In VIP 2001 93% were seen at 12
months and 86% at 24 months. All participants were included in
the analyses and missing values were imputed using the method
of last observation carried forward.
VIM 2005 also appears to be of high quality though there is not
a specific statement about allocation concealment in the study
report. It is probable, however, that this was properly done since
this was the case in all the other trials conducted by this group.
Masking of participants, outcome assessors was maintained. The
ophthalmologist applying the laser light could not be masked to
the fluence allocation but did not know the verteporfin treatment
status.
The VIO 2007 trial is reported as having used a similar protocol
to the VIP 2001 although there is no specific information about
randomisation methods or allocation concealment.
Lack of detailed reports mean that uncertainty remains about bias
in Valio 2007 and Schmidt-Erfurth 2008 (see risk of bias tables).
Effects of interventions
See: Summary of
findings for the main comparison Photodynamic therapy with
verteporfin compared to photodynamic therapy with 5% dextrose
in water for neovascular age-related macular degeneration
The realistic aim of PDT is to slow progression of AMD, not
to produce normal vision. In the original review, outcomes were
therefore expressed as risks of a poor outcome, rather than as im-
provements in vision. However, for the update in 2009, given the
improvements in vision available with other treatments, we felt
that data on the outcome “gain in vision” would be useful for
consumers in particular to compare the effects of PDT with other
available treatments.
Overall analysis (Table 2)
Loss of 3 or more lines of visual acuity
Four trials (1352 participants) provided data on this outcome. At
12 months the pooled risk ratio (RR) of losing 3 or more lines of
visual acuity was 0.78 (95% confidence interval (CI) 0.67 to 0.91)
(Figure 3). At 24 months the pooled RR was 0.80 (95% CI 0.73
to 0.88) (Figure 4). The results were reasonably consistent. All
estimates were in the direction of benefit and confidence intervals
overlapped.The Chi2 test for heterogeneity was P = 0.23 and I2
was 30%.
Figure 3. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.1 Loss of 3 or more lines (15 or more letters) visual acuity at 12 months.
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Figure 4. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.3 Loss of 6 or more lines (30 or more letters) visual acuity at 12 months.
Loss of 6 or more lines of visual acuity
At 12 months the RR of losing 6 or more lines of visual acuity
was 0.70 (95% CI 0.56 to 0.88) (Figure 5). At 24 months the
pooled RR was 0.66 (95% CI 0.53 to 0.83) (Figure 6). As before
the results of the different trials were consistent (Chi2 P = 0.65, I
2 = 0%).
Figure 5. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.2 Loss of 3 or more lines (15 or more letters) visual acuity at 24 months.
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Figure 6. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.4 Loss of 6 or more lines (30 or more letters) visual acuity at 24 months.
Gain of 3 or more lines of visual acuity
Gain in visual acuity was not experienced commonly in the study
cohort - approximately 5% of participants at 12 months and 10%
at 24 months gained 3 or more lines of visual acuity. However,
gain in vision was experienced more often by the treatment group
than the control group. The pooled RR at 12 months was 2.19
(95%CI 0.99 to 4.83) (Figure 7) and the pooled RR at 24months
was 2.55 (95% CI 1.31 to 4.99) (Figure 8). The results of the
different trials were consistent (I2 = 0%).
Figure 7. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.7 Gain of 3 or more lines (15 or more letters) of visual acuity at 12 months.
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Figure 8. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.8 Gain of 3 or more lines (15 or more letters) of visual acuity at 24 months.
Mean number of lines lost
Data on visual acuity as a continuous outcome was reported but
there were limited data on measures of variability so it was not
possible to pool these data. The data available are presented in
Table 3 and Table 4.
On average participants in these studies lost vision over 12 and 24
months (Table 3). In all four studies, the verteporfin treated group
lost fewer letters of visual acuity and average final visual acuity
scores were better in the verteporfin groups (Table 4). The average
difference between the groups ranged from two to 10 letters visual
acuity.
Subgroup analyses
We did not plan any subgroup analyses in our protocol. However,
TAP1999 found differences in treatment effect depending on how
much of the lesion was composed of classic CNV. We therefore
have replicated their subgroup analyses using data from other trials
(Table 5; Figure 9; Figure 10).
13Photodynamic therapy for neovascular age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 9. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.9 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 12
months.
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Figure 10. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.10 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at
24 months.
There was some evidence of a stronger treatment effect in people
with lesion composed of 50% or more classic CNV “predomi-
nantly classic” (pooled RR for loss of 3 or more lines of visual
acuity at 12 months 0.54, 95% CI 0.41 to 0.71) (Figure 9). This
effect was not significantly different from the effect seen in people
who had no evidence of classic CNV (pooled RR at 12 months
0.80, 95% CI 0.67 to 0.96). The least treatment effect seemed to
be observed in the middle group with some classic CNV “mini-
mally classic” (pooled RR 0.90, 95% CI 0.70 to 1.14). This was
statistically significantly different from the result in the “predomi-
nantly classic” group but not the “no classic” group. Similar results
were seen at 24 months (Figure 10).
Evidence of occult choroidal neovascularisation
In TAP 1999 the RRs of losing 3 or more lines of visual acuity at
12 months were 0.90 if occult CNV was present (95% CI 0.73 to
1.11) and 0.34 if occult CNV was absent (95% CI 0.22 to 0.51).
At 24 months, the RRs were 0.88 (95% CI 0.74 to 1.04) and 0.42
(95%CI 0.30 to 0.60) respectively. The test for effectmodification
between these two subgroups was significant. Neither the 95%
confidence intervals nor the 99% confidence intervals for these
two subgroups overlap.
Lesion area composed of classic choroidal neovascularisation
In TAP 1999, the proportion of the lesion comprised of classic
CNV was estimated as 0%; greater than 0% but less than 50%;
greater than 50%. The proportion was unknown in four partici-
pants (three in the treatment group and one in the control group).
The subgroup analyses were therefore based on a total of 399 eyes.
In VIP 2001, the majority of the participants (76%) had “occult
with no classic CNV”. An additional 56 eyes had some classic
CNV (less than 50% but greater than 0% as above). Only 19 eyes
had predominantly classic CNV.
In VIO 2007, all the participants had occult neovascularisation
so could be included with the subgroup analyses from TAP 1999
of patients with no classic lesions and the equivalent subgroup in
VIP 2001.
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The pooled RR for losing 3 or more lines of visual acuity at 12
months for the group with 0% CNV was 0.77 [0.61, 0.97]. In-
cluding patients fromVIO 2007 greatly reduces the effect estimate
by more than 20% from 0.54 if just the TAP 1999 trial patients
are included. Results for 3 ormore lines lost at 12months were not
reported for the other two subgroups in the VIP 2001 study. We
included the participants from VIM 2005 from the placebo and
standard fluence intervention arm with TAP 1999 for the mini-
mally classic subgroup (0 to 50% classic). The RRs for losing 3 or
more lines of visual acuity at 12 months in people with more than
0% but less than 50% CNV was 0.90 (95% CI 0.70 to 1.14) and
0.54 for greater than 50% CNV - participants from TAP 1999
only - (95% CI 0.41 to 0.71) (see Analysis 1.9).
At 24 months the pooled RRs for losing 3 or more lines of visual
acuity were 0.77 (95% CI 0.64 to 0.92), 0.93 (95% CI 0.77 to
1.14) and 0.60 (95% CI 0.48 to 0.75) respectively (see Analysis
1.10). Adding VIM 2005 to the minimally classic group (standard
fluence only) did not materially influence the evidence of ineffec-
tiveness of treatment in this group.
These results suggest there was a reduction in the risk of loss of
vision when classic CNV was absent or when greater than 50%
of the lesion was comprised of classic CNV. However, there was
very little reduction in risk when between 0% and 50% of the
lesion was comprised of classic CNV. However, the test for effect
modification between these three subgroups was not statistically
significant (P = 0.066).
Other primary outcomes
Contrast sensitivity
This outcome from the TAP trial was reported by Rubin 2002.
This wasmeasured in participants at baseline and at three-monthly
intervals after refraction and measurement of best-corrected visual
acuity. Contrast sensitivity was measured using the Pelli Robson
chart (no. 7002251 Clement Clarke, Columbus Ohio). The mea-
surements were made using a standard protocol and illumination
and outcomes were categorised in terms of more than six or more
than 15 letters lost since baseline. A higher proportion of those
treated with placebo lost both more than six and 15 letters of con-
trast sensitivity at 12 and 24 months. The RR of losing 6 lines of
contrast sensitivity by 24 months was 0.47 (95% CI 0.37 to 0.60)
in the PDT group compared to placebo (see Analysis 1.5). For 15
letters the RR was 0.58 (95% CI 0.34 to 0.98) (see Analysis 1.6).
Central visual field function
Thiswas reported by Schmidt-Erfurth (Schmidt-Erfurth2004) for
46 participants of the TAP trial based in Germany. Participants in
this centre had various additional investigations reported including
Scanning Laser Ophthalmoscopic perimetry of the macular in
order to measure the size of the central scotoma in treated and
placebo groups. This was reported as mean area in mm2 The
mean area of the absolute scotoma increased in both groups but
significantly more the placebo arm (2.5 mm2 baseline to 7.3 mm
2 at 24 months in the treated group compared to 2.7 mm2 at
baseline to 31.5 mm2 at 24 months in the placebo group). Similar
findings were reported for differences in the increase in size of the
relative scotoma between groups. These differences were reported
as statistically significant at the level of P < 0.001 though neither
standard errors of these means nor 95% confidence intervals are
provided.
Secondary outcomes
Neovascular membrane morphology
Schmidt-Erfurth’s group also reported on the outcome ofConfocal
Indocyanine Green Angiography on her subgroup of the TAP
trial participants in Germany (Schmidt-Erfurth 2003); in this case
outcomes were reported on 60 participants. It is not clear why
there is a discrepancy between the 60 participants in this analysis
and 46 undergoing measurement of central scotoma as described
above. Presumably 14 participants did not have SLO perimetry
but did have ICG angiography.
This paper reports outcomes in terms of the mean size of the
neovascular membrane in mm2. Forty eyes received PDT and 20
received placebo. Baseline mean areas of ICG leakage were 3.9
mm2 for the PDT group and 2.8 mm2 for the placebo eyes. This
reduced to 3.0 mm2 in the treated group at 24 months compared
to a growth to 9.6 mm2 in placebo eyes. This difference is reported
as highly significant by P value (= 0.008) but no standard errors or
confidence limits are provided apart from graphically represented
error bars which are not specified in the legend.
Quality of life
Evidence of efficacy as described above has still not been substan-
tiated by any quality of life outcomes reported from the TAP or
VIP trials.
Adverse effects
The risk of severe and profound visual loss became clearer in later
reports; two reports from the TAP and VIP investigators (Arnold
2004; Azab 2004) and a large phase 4 open-label study reporting
on the outcomes of verteporfin PDT in 4435 patients called the
VAM study (Bressler 2004b).
Arnold 2004 focuses on the occurrence of acute severe visual acu-
ity decrease (ASVAD). This was defined as at least a 20 letter loss
(equivalent to four lines) within seven days after treatment. Even
though this paper reports this outcome from two RCTs they de-
scribe the study as an observational case series and a fairly detailed
account is given of 15 events in 14 eyes. One of these was later
judged as unlikely to be due to PDT. All but two events occurred
shortly after the first treatment and only in the treated arm. Three
of these events occurred in the TAP trial and ten in the VIP. All
13 events occurred within three days of treatment. The absolute
risk difference for both studies is 0.02 (95% confidence interval
0.01 to 0.03) (Figure 11).
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Figure 11. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.11 Adverse effects: acute severe visual acuity decrease.
Azab 2004 provides these data in the context of all other adverse
events reported for the two trials. This report is described as a
meta-analysis though data are only combined for the two trials for
systemic side effects. The authors found that only visual distur-
bances including ASVAD, injection site reactions, photosensitiv-
ity reactions and infusion-related back pain occurred with greater
frequency in the treated participants (Figure 12).
Figure 12. Forest plot of comparison: 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS
PLACEBO, outcome: 1.14 Adverse effects: infusion-related back pain.
TheVAMstudy (Bressler 2004b reports on outcomes from a larger
number of patients recruited from 222 centres in North America
(10 times the number in TAP) between September 1999 and June
2000 when the verteporfin became commercially available. Max-
imum follow up was therefore nine months. About half the study
population had six months follow up. This study provides further
information on the risk of adverse events outside a RCT setting
but as this is an open label studywith no comparator group; RRs or
risk differences (and hence number needed to harm (NNH)) can-
not be calculated. One series from the Wilmer (Do 2004) reports
this outcome in 52 patients but unfortunately the denominator
was not given (the overall number of persons and eyes receiving
PDT). Vision loss can be profound is this group and data from
TAP and VIP suggest it may be more likely to occur in people
with better initial visual acuity.
Reports of visual disturbance (reports of “abnormal vision”, “de-
creased vision” and visual field defect) occurred in one in every
four people taking part in the TAP 1999 and VIP 2001 stud-
ies. This is perhaps unsurprising as participants had neovascular
AMD. However, people treated with verteporfin were more likely
to report visual disturbance (pooled RR 1.61, 95% CI 1.24 to
2.09) (Analysis 1.12). Presumably this visual disturbance must
have been reasonably transient as visual outcomes at 12 and 24
months were better in the treatment group. 2.4% of people treated
with verteporfin experienced infusion-related back pain and 2.4%
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had photosensitivity reactions. Problems with the injection site
occurred in 13.1% of people treated with verteporfin compared
to 5.6% people in the control group. Few allergic reactions were
seen and these were equally likely in treatment and control groups.
Adding data from VIM 2005 for adverse outcomes did not mate-
rially affect the risk estimates.
The VIM 2005 study findings seem to suggest that the reduced
fluence treatment is as or more effective than standard fluence and
that both are better than placebo for relatively small minimally
classic lesions that were selected for the trial. These smaller lesions
were selected for the trial because retrospective analysis (or post
hoc) of the 0 to 50% minimally classic group in the TAP and VIP
studies suggested smaller lesions had a better outcome to the larger
ones.Waiting forminimally classic to become predominantly clas-
sic did not appear to improve the outcome and the authors suggest
the trial provides evidence for earlier treatment of smaller mini-
mally classic lesions with verteporfin though they are less certain
about the benefit of lower fluence and suggest the need for more
evidence.
Economic outcomes
No economic analyses have been reported from either TAP, VIP
or VIM but a number of separate economic evaluations have now
been published.
D I S C U S S I O N
The absence of any effective treatment for neovascular AMD (ex-
cept for the few in whom laser photocoagulation works) meant
that there was intense interest in PDT for the many millions of
sufferers of the disease worldwide when it was first made available.
With the arrival of the anti vascular endothelial growth factor an-
tibody preparations, the interest in PDT is waning though its use
may continue in combination with these and intraocular steroids.
Unfortunately PDT, like photocoagulation, can be effective only
during the proliferative stage of the disease while the neovascular
process is active. It cannot have any effect once sight is lost and
the scarring process is complete. Therefore, like so many other
degenerative processes of the neuroretina, nothing can be done to
restore function once the damage is done. Most sufferers of the
condition have established sight loss and, for these, the publicity
surrounding the launch of Visudyne (verteporfin) will have raised
false hopes just as the new agents now available will do. This re-
view indicates that for people with active neovascular disease pho-
todynamic therapy can prevent vision loss. This is corroborated
by additional outcome measures such as contrast sensitivity, size
of central scotoma and neovascular membrane dimensions.
A key question is how long the effect of treatment will last and
whether repeated treatments would be required in the longer term.
This review indicates that treatment benefits last for at least two
years. An open-label extension of the TAP 1999 study indicated
that vision outcomes remained relatively stable from 24 to 48
months (TAP 2002). Report of five year outcomes suggest it re-
mains stable in those who remained in follow up (Kaiser 2006).
Another important issue is howmany presenting patients will ben-
efit from photodynamic therapy. In addition to the problem of
accessing specialist services in time, there is the question of the
proportion of lesions that will actually be treatable. The evidence
reported here suggests that purely classic neovascular membranes
do better. Subgroup analysis of the TAP 1999 study suggested that
PDT is less effective when occult CNV is present. Occult vessels
mean that the extent of the membrane cannot be clearly defined
and so it is not surprising that treatment is found to be less ef-
fective because the laser cannot be aimed at the entire membrane.
However, the VIP 2001 study recruited mostly patients with oc-
cult neovascularisation and demonstrated a treatment benefit of
photodynamic therapy at 12 and 24 months. However, the VIO
2007 trial also selected patients with occult CNV and did not
demonstrate a significant effect of treatment but combining all
the patients with occult lesions from TAP, VIP and VIO showed a
small significant effect. Pooled analysis of the TAP 1999 and VIP
2001 studies in this review showed no statistically significant dif-
ference in treatment effects in subgroups defined by the presence
or absence of classic CNV. This observation has been noted by
other authors. For example, Meads 2004 casts serious doubt on
the validity of the subgroup analyses.
Subsequent reports of exploratory analyses have been published
from the TAP trials (Bressler 2002) and from the TAP and VIP
trials (Blinder 2003) which find only lesion size (the smaller lesions
do better) and poorer presenting acuity (perhaps less vision to lose)
were predictors of better outcome. One other report from TAP
(Bressler 2004a) examined the natural history of minimally classic
lesions which had a poorer outcome in the TAP trial treated group.
Of the 207 randomised to the placebo group 98 had minimally
classic lesions of which 39 progressed to become predominantly
classic (21 of these within three months). The suggestion here is
that it might be advisable to wait for minimally classic lesions to
progress to become predominantly classic so that potential effec-
tiveness of PDTmight be greater. The authors imply that this need
not necessarily be at the expense of allowing the lesion to become
very large or indeed the vision to deteriorate. A more recent report
from the VIP trial comes to similar conclusions (Pieramici 2006).
We are not told in the available reports the extent to which clini-
cians and indeed the trial Photograph Reading Center personnel
were able to agree about the subgroup classification of classic or
occult lesions. It is likely that there is much variation in opinion
on this. The necessary skill to report on fluorescein angiograms
and recognise different lesion types is highly refined. Most experts
assert that stereo images are required to be able to locate the posi-
tion in depth of staining or fluorescein leaks. Stereophotography
requires either a dedicated camera equipped to take simultaneous
stereo images or a skilled photographer who takes sequential im-
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ages slightly laterally displaced from one another, providing a non-
simultaneous or pseudo-stereo image. However, the guidelines for
reporting angiograms and data on interobserver agreement have
now been published for the TAP and VIP trials (Barbazetto 2003).
A lot of detail is given on reporting guidelines but the information
on agreement is somewhat brief though reported kappa values for
the main subgroup criteria were good. This was based on a 10%
subsample of graded photographs. Another independent study has
reported on agreement within and between 16 different specialists
in Germany (Holz 2003) for the same angiographic criteria as for
TAP and VIP. Agreement was not quite so good for both intra and
interobserver agreement as for the reporting centre for the trials
but was acceptable nevertheless.
The natural history of the growth of subretinal membranes varies
from individual to individual. They may be aggressive and rapidly
growing or indolent. This is the kind of individual factor that
will influence the likelihood of a patient being in a position to
benefit from this treatment. The trial report does not comment
on the proportion of participants presenting to the trial centres
that had treatable lesions. The verbal estimate from one trialist
was approximately 25% and from another expert between 5% and
7%. This is of crucial importance in estimating the impact of this
new treatment on healthcare budgets.
Age-related macular degeneration is a bilateral disease although
one eye is usually affected before the other.With a lesion present in
one eye, the annual cumulative incidence of a lesion in the second
eye is estimated to be about 15%.Clinicians now commonly advise
patients with a lesion in one eye to be watchful for the onset
of symptoms in the second eye and to present as soon as those
symptoms are noticed to improve the chances of catching the
lesion in the second eye in time. This often entails the provision of
an Amsler grid, a simple chart on which a number of gridlines are
printed around a central fixation spot. The patient is instructed to
examine the grid and to look for focal distortion of the lines in the
grid which would indicate local elevation of the retina as a result
of the growth of an underlying membrane. This strategy offers the
best hope of saving sight with this new treatment at least in places
where access to a qualified ophthalmologist can be slow.
It should also be recalled that this treatment does not restore sight
but rather prevents further deterioration. Sustaining numerous as-
sessments which involve relatively invasive treatments may have
an adverse effect on the patient. Without patient-orientated out-
comes in these trials we cannot comment on the patient’s perspec-
tive on the experience of Visudyne therapy. It is likely that in most
cases, especially where loss of sight of the second eye is threatened,
patients will be willing to undergo all the necessary interventions,
even when the probability of success is small.
Quality of life outcomes have been independently reported in a
cohort of individuals treated with PDT and followed for one year
(Armbrecht 2004). There was no comparator group. At 12months
participants were less anxious andmore independent than baseline
though there was a significant deterioration in more vision-related
tasks.
Adverse effects occurred infrequently with the exception of the
rather vague “visual disturbance” which affected more people in
the verteporfin group compared to the control group. However,
this was not reflected in the visual acuity outcomes. Infusion-
related back pain occurred in 2.4% which is substantially lower
than in some other studies. For example, in a series of 250 people
treated with verteporfin 9.6% experienced verteporfin-associated
pain, most of which was back pain (Borodoker 2002). It is now
clear that acute severe visual acuity decrease is a relatively small
but serious risk of poor outcome of treatment.
The trials included in this review appear to have been performed
to high standards and were closely supervised by the Food and
Drugs Administration of the USA. Both TAP and VIP trials were
sponsored by the manufacturers of the drug (CIBA Vision and
Novartis Ophthalmics) and declared potential conflicts of interest
exist for a number of the trialists who hold interests in the man-
ufacturer of the laser technology. This makes detailed scrutiny of
reports of the trial essential. Of concern are the numerous protocol
revisions that were registered with the Institutional Review Bodies
throughout the study and after completion of follow up. Although
we have not yet had access to the main protocol or to the revisions,
a CIBA representative has assured us that the changes were not
substantive and, in particular, that there were no changes to the a
priori determinants of the primary outcomes.
As far as studies on populations other than north American and
European, the Japan 2002 study provides evidence albeit uncon-
trolled that PDT works as well in Japanese people but there is no
evidence of effectiveness in other population groups.
New reviews have not drawn any conflicting conclusions or any
additional evidence. In particular, the review commissioned by
the National Health Service’s Research and Development Health
Technology Assessment Programme on behalf of the National In-
stitute of Clinical Excellence (NICE) in the UK (accessible at http:
//www.nice.org.uk) was in accordance with the findings of our re-
view but went on to perform a detailed cost and cost-utility analy-
sis. They concluded through economic modelling that the benefits
of PDT with verteporfin at two years were “at best at the margins
of what is generally considered to be an efficient use of health care
resources”.
Another paper fromAustralia (Hopley2004) examined cost-utility
for PDT for predominantly classic neovascular AMD using data
from theTAP trial in two cost-utilitymodels for two case scenarios.
They conclude that as the only available treatment for some forms
of neovascular AMD, PDT can be considered moderately cost
effective for those with reasonable acuity but less so for those
with poorer presenting vision. These conclusions depend upon the
validity of the subgroup analyses of the TAP trial and there must
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be some concern that one of the conclusions of the trialists post
hoc analyses that those with poorer presenting vision fare better
in terms of numbers of lines of visual acuity lost.
The NICE review concluded that there was still much uncertainty
about the effectiveness of this treatment. In the face of enormous
pressure to provide something that might work when nothing else
is available, provision of service conditional on close monitoring
of outcomes is a pragmatic approach, though implementation of
this policy is difficult. However a cohort study monitoring the
outcomes of PDT (including quality of life) provided by the Na-
tional Health Service in the UK was commissioned by the NHS
HTA. The results of this are not yet available.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides evidence that PDT in people with classic
and occult CNV due to AMD is effective in preventing visual
loss. On the basis of existing evidence, approximately eight people
need to be treated with an average of five treatments over two
years to prevent one person losing 3 or more lines of visual acuity.
Approximately 1 in every 100 treated patients will have an acute
severe loss of vision in the treated eye. For an expensive treatment
there are questions about the cost-utility and indeed opportunity
cost for health services, especially when resources are limited.
Three out of the four trials included in this review were performed
by the same investigators using largely the same clinical centres and
funded bymanufacturers of verteporfin. As for all new technology,
outcomes and potential adverse effects need to bemonitored when
introduced into clinical practice and this recommendation has
been implemented in the UK by the establishment of a national
cohort study to monitor outcomes of verteporfin PDT according
toNICE guidelines in theNHS. The initial findings of this cohort
outcome study should be published within the next year.
There are major implications for health services, both in terms of
potential expenditure and organisation, if PDT and indeed other
new treatments for AMD are to be introduced. Where referral to
an ophthalmologist is through a primary care network, facilities
for the recognition of this condition in its early stages are needed.
There is potential for an enormous increase in referral of people
with early age-related maculopathy for assessment, in case an early
treatable lesion is present. This could swamp already overstretched
facilities at the secondary care level. Extra resources will be required
at the secondary care level to manage increased referrals, for the
necessary technology to diagnose treatable lesions and to deliver
treatment.
All the above concerns have become less relevant for PDT since its
use has been largely replaced by antivascular endothelial growth
factor intraocular injections though they remain relevant for this
new treatment.
Implications for research
Further independent trials of verteporfin are required to establish
that the effects seen in this study are consistent and to examine
important issues not yet addressed, particularly relating to quality
of life and cost.
A similar recommendationwasmade by the authors commissioned
for NICE for publicly-funded pragmatic trials with economic and
vision-related quality of life outcomes over a longer time scale. To
our knowledge no such studies are underway. Some commentators
argue that technology is progressing at a pace that will render such
studies irrelevant. New interventions for AMD, particularly those
based on drugs active against Vascular Endothelial Growth Factor,
show some promise and there is speculation that the role of PDT-
based treatments will be short-lived. It is now unlikely that new
studies on PDT alone will be initiated.
Descriptive epidemiology on the population at risk and the num-
bers likely to benefit from these kinds of interventions remains
essential to estimate the impact of these new treatments on health
service resources and the well being of the ageing population of
more affluent countries with a life-expectancy sufficient to render
AMD a significant public health concern. A particular concern re-
mains that people in need of treatment can access it equitably and
in time. Health services research of this nature and surveillance for
rare but severe adverse effects is required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Schmidt-Erfurth 2008
Methods Prospective, randomized, multicenter clinical trial.
Participants Two hundred three patients with predominantly classic CNV secondary to AMD
Interventions During the first 6 months of VT, patients underwent retreatment every 2 (group A) or 3
(group B) months. After 6 months, both groups underwent retreatment every 3 months
for as long as CNV activity was documented
Outcomes The primary outcome of the study was best-corrected mean visual acuity as measured us-
ing the Early Treatment Diabetic Retinopathy Study protocol. The secondary outcomes
were percentage of patients losing at least 3 lines of vision, percentage of patients gaining
at least 1 line of vision, and lesion size based on the greatest linear dimension (GLD)
documented by fluorescein angiography, impact of initial lesion size, and retreatment
rate as well as safety
Notes Published as two separate reports of 12 and 24 month outcomes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information on how the allocation se-
quence was generated.
Allocation concealment? Unclear No information on allocation concealment
provided.
Blinding?
All outcomes
Unclear No information provided on whether ob-
servers of primary outcome measures were
masked to treatment status
Incomplete outcome data addressed?
12 month follow up
Yes “In both treatment groups, at least 90%
of patients completed the 12-month fol-
low-up.” Therefore incomplete outcome
data unlikely to have introduced bias at 12
months
Incomplete outcome data addressed?
24 month follow up
No “Fifty-three percent of patients in group A
and 59% in group B completed the 2-year
follow-up.” Such a large loss to follow up
must lead to serious doubts about the va-
lidity of the study findings at 2 years even
without serious imbalance between the two
groups
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Schmidt-Erfurth 2008 (Continued)
Free of selective reporting? Yes Primary and secondary outcomes clearly
and consistently reported in both study pa-
pers
TAP 1999
Methods Randomised controlled trial: one eye per patient was randomised in a 2:1 (treatment:
control) ratio
Participants 609 people with subfoveal CNV lesions caused by AMD with evidence of classic CNV
and best corrected acuity of approximately 20/40 to 20/200
Interventions Photodynamic therapy following verteporfin injection versus photodynamic therapy
following intravenous 5% dextrose
Outcomes Visual acuity at 12 and 24 months.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Random assignments were prepared by
the statistical department of CIBA Vision
Corp. Sealed envelopes with random as-
signmentswere prepared by theQualityAs-
surance
Department within QLT PhotoTherapeu-
tics Inc (Vancouver, British Columbia),
which maintained independence from any
other function of the trials.” TAP report 1,
page 1331
Allocation concealment? Yes “The allocation of verteporfin therapy or
placebo was recorded on a randomization
log that was stored in a locked cabinet with
both opened and unopened randomization
envelopes at each clinical center.” TAP re-
port 1, page 1331
Blinding?
All outcomes
Yes “The study coordinator aware of the treat-
ment assignment and anyone else who
might assist in the setup of verteporfin or
placebo solutions were trained to make ev-
ery reasonable attempt to maintain mask-
ing
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TAP 1999 (Continued)
of the ophthalmologist, patient, vision ex-
aminer, and Photograph Reading Center
personnel. The verteporfin and placebo so-
lutions were different colors (green vs col-
orless). All verteporfin and placebo solu-
tions as well as the intravenous tubing were
covered entirely with foil so that the pa-
tient and treating ophthalmologist were
masked during the infusion. The ophthal-
mologist remained masked while adminis-
tering the light since the fundus appearance
during treatment does not change in any
way to indicate verteporfinor placebo treat-
ment. On thematerials submitted to them,
the Photograph Reading Center graders
did not have any information to indi-
cate that verteporfin or placebo was ad-
ministered. The marked hypofluorescence
within a treated area noted within 1 week
after verteporfin therapy in phase 1 and 2
studies is not readily apparent 3 months af-
ter treatment. Therefore, this hypofluores-
cence was not judged to be a likely source
of potential unmasking of the graders eval-
uating photographs obtained at least 3
months after verteporfin therapy. Clinic
monitors also had no access to informa-
tion that would indicate treatment assign-
ment. There were no known instances of
unmasking of the vision examiners or Pho-
tograph Reading Center graders. Only 2
patients who noted a green solution fol-
lowing extravasation of drug were likely
unmasked. Treating ophthalmologists, but
not the patients, were unmasked in 4 ad-
ditional cases. In 2 of these cases, fluores-
cein angiography was obtained within 1
week after treatment to evaluate severe vi-
sual acuity decrease and showed hypoflu-
orescence typical for verteporfin therapy.
In another case the ophthalmologist noted
the green verteporfin leaking onto the cover
over the intravenous solution, and in 1 ad-
ditional case, the ophthalmologist became
unmasked prior to a vitrectomy for a sub-
retinal hemorrhage; the patient had been
assigned to placebo.” TAP report 1, page
1331
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TAP 1999 (Continued)
Incomplete outcome data addressed?
12 month follow up
Yes Follow-up good and equal between both
groups. 94% of patients within each group
completed the month 12 follow-up exam-
ination. 379/402 in verteporfin group and
194/207 in placebo group.TAP report 1,
figure 1, page 1335
Incomplete outcome data addressed?
24 month follow up
Yes Follow-up equal between both groups.
351/402 (87%) of patients PDT group
completed the month 24 follow-up exam-
ination compared to 178/207 (86%) of
placebo group. TAP report 2, figure 1, page
201
Free of selective reporting? Unclear Unlikely for primary analysis of treatment
versus control but possible for subgoup
analyses by lesion type. Nomention of pro-
posed subgroup analyses in power state-
ment and discussion suggests exploratory
analysis of data eg. “To explore these sub-
group findings further, visual acuity
distributions (Figure 9), mean change in
contrast sensitivity (Table 6), and angio-
graphic outcomes (Table 6) at the month
12 examination were evaluated, based on
lesion components noted at baseline. The
lesion components at baseline affected the
magnitude of the treatment
benefit with respect to the visual acuity dis-
tributions.” TAP report 1, page 1340
The protocol for this study was not inde-
pendently published prior to this first re-
port of results but contactwith the commu-
nicating author provided an assertion that
subgoup analyses were planned a priori
Valio 2007
Methods Altered light treatment using delayed light after Visudyne in occult AMD
Participants 60 patients enrolled at 7 centres in the USA.
Interventions Participants randomised 1:1 to receive verteporfin injection followed by delayed or stan-
dard light application. The assigned treatment was repeated every three months if fluo-
rescein leakage was detected
Outcomes Visual acuity at least 6 months.
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Valio 2007 (Continued)
Notes Published as a short report in the American Journal of Ophthalmology with additional
details on line
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Patients were “randomised” but no infor-
mation on how the sequence generation is
provided in the protocol details available at
AJO.COM
Allocation concealment? Unclear No information on allocation concealment
provided online as above at AJO.COM
Blinding?
All outcomes
Yes “All outcome assessors, including vision ex-
aminers, photographers, treating ophthal-
mologists, DARC (reading centre) graders,
and clinic monitors, were masked to the
treatment assignment. The ophthalmolo-
gist was asked to leave the room for at least
30 minutes before treatment and did not
return for the light application until noti-
fied by the study coordinator.” “During the
trial, investigators were not unmasked to
the treatment assignment for any patient.
The success of masking was not evaluated
formally.”
Incomplete outcome data addressed?
12 month follow up
Yes A CONSORT flow chart is provided at
AJO.COM which shows 82% 12 month
follow up in the standard light arm and
81% in the delayed light arm
Incomplete outcome data addressed?
24 month follow up
Yes Not relevant
Free of selective reporting? Yes Unlikely since the insignificant primary
outcome measure is clearly stated
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VIM 2005
Methods Randomised controlled trial: One eye of each patient was enrolled. No information on
allocation concealment is provided but double masking is described. Participant were
randomised to Verteporfin or placebo in a 2:1. Patients were also randomised 1:1 into
two groups of fluence, reduced and standard in which the reduced group had less intense
illumination of the photodynamic dye as it passed through the neovascular membrane
Participants 117 patients with minimally classic CNV due to AMD.
Interventions Photodynamic therapy following verteporfin injection versus photodynamic therapy
following intravenous 5% dextrose. Participants in the placebo and treatment groups
were also randomised to Standard Fluence (SF) intensity of illumination equivalent to
a light dose of 50 Joules per square centimetre amd a Reduced Fluence (RF) equivalent
to 25 Joules per square centimetre
Outcomes Visual acuity at 12 and 24 months.
Acute severe visual acuity loss.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Patients were randomly assigned to 1 of
2 fluence groups; at the same time, pa-
tients were randomly assigned to received
verteporfin therapy or placebo.” Main re-
port published Archives of Ophthalmology
2005, page 450
Allocation concealment? Yes Allocation concealment not specifically
mentioned but probably adequate as was
well dealt with in all the other studies from
this group.“All study participants and out-
come assessors, including vision examiners,
photographers, ophthalmologists, Photo-
graph Reading Center personnel and clinic
monitors, were masked to the treatment as-
signment.”Main report publishedArchives
of Ophthalmology 2005, page 450
Blinding?
All outcomes
Yes “All study participants and outcome asses-
sors, including vision examiners, photogra-
phers, ophthalmologists, Photograph read-
ing Center personnel and clinic monitors,
were masked to the treatment assignment.
The ophthalmologist responsible for apply-
ing the laser light was notmasked to the flu-
ence rate because the treating ophthalmol-
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VIM 2005 (Continued)
ogist was responsible for the light fluence
rate being applied to the study participant’s
retina.Only the study coordinators and any
other person who might assist in the setup
of verteporfin or placebo solutions were
aware of the treatment assignment with re-
spect to verteporfin or placebo; these in-
dividuals were trained to make every rea-
sonable attempt to maintain masking of
participating patients and all other study
personnel. However treatment assignment
was unmasked for a total of 3 patients.
Investigators were unmasked to the treat-
ment assignment of 2 patients. One pa-
tient was identified by the Reading Center
as having a predominantly classic lesion at
the initial visit; the other was identified by
the Reading Center as having a predomi-
nantly classic lesion at the 6-week exami-
nation. In both cases the treating ophthal-
mologist believed that verteporfin therapy
should not be delayed until the next sched-
uled visit. A third patient was inadvertently
unmasked to the sponsor by the study co-
ordinator at the site were the patient was
being treated because the coordinator asked
the sponsorwhat the site should dowith the
reconstituted vial of verteorfin, thus indi-
rectly and inadvertently revealing the treat-
ment assignment for a particular randomi-
sationnumber. The success ofmasking oth-
erwise was not evaluated formally” Main
report published Archives of Ophthalmol-
ogy 2005, page 450
Incomplete outcome data addressed?
12 month follow up
Yes Follow-up good and equal between groups.
38/40 (95%) of placebo group seen at
12 months compared to 36/38 (95%) of
reduced fluence group and 36/39 (92%)
of the standard fluence group. Main re-
port published Archives of Ophthalmology
2005, figure 1, page 451
Incomplete outcome data addressed?
24 month follow up
Unclear Follow-up a little lower in the treatment
groups. 37/40 (93%) of placebo group seen
at 24 months compared to 34/38 (89%)
of reduced fluence group and 32/39 (82%)
of the standard fluence group. Main re-
port published Archives of Ophthalmology
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VIM 2005 (Continued)
2005, figure 1, page 451
Free of selective reporting? Unclear Primary outcome specified but secondary
outcomes less clearly specified. Main out-
come of interest to this review reported
VIO 2007
Methods 2-year randomized, placebo-controlled, double-masked, multi-centre, Phase III study of
the treatment of occult with no classic subfoveal CNV lesions secondary to AMD using
Visudyne therapy compared with placebo
Participants 364 people over 50 years with occult but no classic CNV due to AMD enrolled at 43
centres in North America randomised 2:1 active versus placebo treatment. “The VIO
study was to confirm the treatment effect shown in patients with occult CNV and
evidence of recent disease progression in theVIP AMD study.Most of the patients in VIP
AMD study had occult with no classic CNV (258 of 339 patients: 76%). Nevertheless,
VIO study included amore restricted patient population who showed a greater treatment
benefit in the VIP AMD study.”
Interventions Visudyne administered as a 10minute intravenous infusion followed 15minutes after the
start of the infusionby light applicationof 600mW/cm2 for 83 seconds (dose of 50J/cm2 )
. Treatments maybe repeated every 3 months in the event of recurrent neovascularisation
up to a maximum of 4 treatments in a year. No information is provided in the report
about how the double masked placebo intervention was delivered
Outcomes “Four co-primary analyses of the patients’ responder rates were planned: proportion of
patients who lose, at Month 12 and at Month 24, fewer than 15 letters (<3 lines) and
fewer than 30 letters (<6 lines) of best-corrected visual acuity in the study eye from
baseline.”
Notes Trial was sponsored by Novartis Pharma AG and QLT Inc (see http://clinicaltrials.gov/
ct2/show/NCT00121407?term=NCT00121407&rank=1)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Patients were randomly assigned to
verteporfin or
placebo in a 2 : 1 ratio”. Patients and meth-
ods page 1854. .
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
Unclear “All study participants and outcome asses-
sors were masked to the treatment assign-
ment” Patients and methods page 1854.
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VIO 2007 (Continued)
Incomplete outcome data addressed?
12 month follow up
Yes At 12 months 219/244 (90%) verteporfin
and 111/364 (93%) placebo group given
visual acuity assessment. Figure 1, page
1856.
Missing data were imputed using last ob-
servation carried forward
Incomplete outcome data addressed?
24 month follow up
Yes “At month 24, 198/244 patients (81%) in
the verteporfin group and 108/120 (90%)
patients in the placebo group had a VA as-
sessment (Figure 1).” Results page 1855
Missing data were imputed using last ob-
servation carried forward
Increased death rate in intervention arm at-
tributed to chance alone
Free of selective reporting? Unclear No prior publication of trial protocol
VIP 2001
Methods Randomised controlled trial: one eye per patient was enrolled. Randomisation in sealed
envelopes stratified by clinical centre
Participants 339 people with subfoveal CNV caused by AMD.
Interventions Photodynamic therapy following verteporfin injection versus photodynamic therapy
following intravenous 5% dextrose
Outcomes Visual acuity at 12 and 24 months.
Secondary outcomes include contrast sensitivity and changes in angiographic outcomes
Notes Randomised 2:1 to verteporfin treatment.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Random assignments were prepared by
Statprobe (Ann Arbor, MI). Statprobe also
prepared sealed envelopes with random as-
signments and distributed them to the clin-
ical centers. Patients were randomized in
a ratio of 2:1 to verteporfin treatment or
placebo (to gather more safety data on pa-
tients receiving verteporfin), with only one
eye of a patient to be randomized. For
cases in which an enrolling ophthalmol-
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VIP 2001 (Continued)
ogist believed that both eyes of a patient
were eligible, the patient and ophthalmol-
ogist chose which eye would be enrolled
in the study. Randomization was stratified
by clinical center. Separate groups of color-
coded envelopes were used to distinguish
patients participating in the VIP Trial with
pathologic myopia from those with AMD.
A study coordinator was instructed to open
the sealed envelope only after a patient was
judged to meet all of the eligibility criteria
and only after the enrolling ophthalmolo-
gist and the patient agreed to the patient’s
participation in the trial. Treatment was to
begin the same day that the treatment as-
signment was revealed by opening the en-
velope.” VIP report number 1, page 843
Allocation concealment? Yes See above
Blinding?
All outcomes
Yes “Maskingwas carried out in amanner iden-
tical to procedures followed in the TAP In-
vestigation.7 All patients were to remain
masked until all of themhad completed the
month 24 examination and the data col-
lection and entry was completed.” VIP re-
port number 1, page 843 referring to TAP
report number 1 (see risk of bias table for
TAP study)
Incomplete outcome data addressed?
12 month follow up
Yes Follow-up good and similar between
treatment groups. 210/225 (93%) in
verteporfin group and 104/114 (91%) seen
in placebo group at 12 months. VIP report
number 2, figure 1, page 548
Incomplete outcome data addressed?
24 month follow up
Yes Follow-up good and similar between
treatment groups. 193/225 (86%) in
verteporfin group and 99/114 (87%) seen
in placebo group at 24 months. VIP report
number 2, figure 1, page 548
Free of selective reporting? Yes Usual vision and clinical outcomes re-
ported and report suggests these were de-
cided a priori
AMD: age-related macular degeneration
CNV: choroidal neovascularisation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ADD-V Nodetailed publication ever found butwas a study looking at the effect of combining photodynamic therapy
with an anti-inflammatory agent so falls outside the remit of this review
Japan 2003 Non-randomised open label case series
Schmidt-Erfurth 1999 Non-randomised open-label phase I and II trial
Characteristics of studies awaiting assessment [ordered by study ID]
VER 2004
Methods Prospective randomised controlled trial randomised 1:1 to standard or more frequent photodynamic therapy treat-
ments
Participants People with predominantly classic choroidal neovascularisation. 323 people at 31 sites enrolled
Interventions Visudyne therapy every 3 months (standard) versus more frequent regiment every 1.5 months
Outcomes Mean visual acuity decrease, proportion of participants losing 15 letters or more from baseline
Notes Methods reported as ARVO abstract in 2001 and twelve month outcomes reported again as an ARVO abstract in
2004. In 2005, an abstract published by the macula disease society published the 24 month outcomes. The 12 month
results were also published in German in 2004 in the Spektrum der Augenheilkunde and we are currently seeking a
copy for translation
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D A T A A N D A N A L Y S E S
Comparison 1. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Loss of 3 or more lines (15 or
more letters) visual acuity at 12
months
4 1386 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.69, 0.93]
2 Loss of 3 or more lines (15 or
more letters) visual acuity at 24
months
4 1381 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.73, 0.88]
3 Loss of 6 or more lines (30 or
more letters) visual acuity at 12
months
4 1305 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.56, 0.88]
4 Loss of 6 or more lines (30 or
more letters) visual acuity at 24
months
4 1381 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.53, 0.83]
5 Loss of 6 or more letters of
contrast sensitivity at 24
months
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Loss of 15 or more letters of
contrast sensivitiy at 24 mths
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Gain of 3 or more lines (15 or
more letters) of visual acuity at
12 months
3 941 Risk Ratio (M-H, Random, 95% CI) 2.19 [0.99, 4.83]
8 Gain of 3 or more lines (15 or
more letters) of visual acuity at
24 months
3 941 Risk Ratio (M-H, Random, 95% CI) 2.55 [1.31, 4.99]
9 Subgroup analysis: lesion area
composed of classic CNV. Loss
of 3 or more lines at 12 months
4 1267 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.68, 0.87]
9.1 No classic CNV 3 645 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.67, 0.96]
9.2 Classic CNV > 0% to <
50%
2 379 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.70, 1.14]
9.3 Classic CNV > 50%
(predominantly classic)
1 243 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.41, 0.71]
10 Subgroup analysis: lesion area
composed of classic CNV. Loss
of 3 or more lines at 24 months
4 1375 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.73, 0.89]
10.1 No classic CNV 3 683 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.72, 0.95]
10.2 Classic CNV > 0 to <
50%
3 431 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.77, 1.10]
10.3 Classic CNV > 50%
(predominantly classic)
2 261 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.48, 0.75]
11 Adverse effects: acute severe
visual acuity decrease
3 1075 Risk Ratio (M-H, Fixed, 95% CI) 3.75 [0.87, 16.12]
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12 Adverse effects: visual
disturbance
3 1075 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [1.21, 2.01]
13 Adverse effects: injection site 3 1075 Odds Ratio (M-H, Fixed, 95% CI) 2.09 [1.29, 3.39]
14 Adverse effects: infusion-related
back pain
4 1439 Risk Ratio (M-H, Fixed, 95% CI) 9.93 [2.82, 35.02]
15 Adverse effects: allergic
reactions
2 948 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.34, 2.56]
16 Adverse effects: photosensitivity
reactions
2 948 Odds Ratio (M-H, Fixed, 95% CI) 5.37 [1.01, 28.60]
17 Subgroup analysis: lesion area
composed of classic CNV. Loss
of 3 or more lines at 12 months
3 662 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.67, 0.97]
17.1 No classic CNV 2 588 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.69, 1.01]
17.2 Classic CNV > 0% to <
50%
1 74 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.31, 1.09]
17.3 Classic CNV > 50%
(predominantly classic)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18 Subgroup analysis: lesion area
composed of classic CNV. Loss
of 3 or more lines at 24 months
3 766 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.74, 0.97]
18.1 No classic CNV 2 622 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.73, 0.98]
18.2 Classic CNV > 0 to <
50%
2 125 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.63, 1.20]
18.3 Classic CNV > 50%
(predominantly classic)
1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.42, 1.19]
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Analysis 1.1. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 1 Loss of 3 or more lines (15 or more letters) visual acuity at 12 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 1 Loss of 3 or more lines (15 or more letters) visual acuity at 12 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
TAP 1999 156/402 111/207 38.9 % 0.72 [ 0.61, 0.86 ]
VIM 2005 10/36 18/38 5.4 % 0.59 [ 0.31, 1.09 ]
VIP 2001 114/225 62/114 31.4 % 0.93 [ 0.75, 1.15 ]
VIO 2007 91/244 54/120 24.3 % 0.83 [ 0.64, 1.07 ]
Total (95% CI) 907 479 100.0 % 0.80 [ 0.69, 0.93 ]
Total events: 371 (PDT), 245 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.26, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.91 (P = 0.0036)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.2. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 2 Loss of 3 or more lines (15 or more letters) visual acuity at 24 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 2 Loss of 3 or more lines (15 or more letters) visual acuity at 24 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
TAP 1999 189/402 129/207 43.5 % 0.75 [ 0.65, 0.88 ]
VIM 2005 17/32 23/37 5.7 % 0.85 [ 0.57, 1.29 ]
VIP 2001 121/225 76/114 30.4 % 0.81 [ 0.68, 0.96 ]
VIO 2007 114/244 63/120 20.4 % 0.89 [ 0.72, 1.11 ]
Total (95% CI) 903 478 100.0 % 0.80 [ 0.73, 0.88 ]
Total events: 441 (PDT), 291 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.42 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.3. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 3 Loss of 6 or more lines (30 or more letters) visual acuity at 12 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 3 Loss of 6 or more lines (30 or more letters) visual acuity at 12 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
TAP 1999 59/402 49/207 44.8 % 0.62 [ 0.44, 0.87 ]
VIM 2005 3/36 6/38 3.0 % 0.53 [ 0.14, 1.95 ]
VIP 2001 37/166 30/92 30.9 % 0.68 [ 0.45, 1.03 ]
VIO 2007 39/244 20/120 21.3 % 0.96 [ 0.59, 1.57 ]
Total (95% CI) 848 457 100.0 % 0.70 [ 0.56, 0.88 ]
Total events: 138 (PDT), 105 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.25, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.10 (P = 0.0019)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.4. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 4 Loss of 6 or more lines (30 or more letters) visual acuity at 24 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 4 Loss of 6 or more lines (30 or more letters) visual acuity at 24 months
Study or subgroup Treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
TAP 1999 73/402 62/207 34.5 % 0.61 [ 0.45, 0.81 ]
VIM 2005 4/32 13/37 4.7 % 0.36 [ 0.13, 0.98 ]
VIP 2001 67/225 54/114 36.6 % 0.63 [ 0.48, 0.83 ]
VIO 2007 55/244 30/120 24.2 % 0.90 [ 0.61, 1.33 ]
Total (95% CI) 903 478 100.0 % 0.66 [ 0.53, 0.83 ]
Total events: 199 (Treatment), 159 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.35, df = 3 (P = 0.23); I2 =31%
Test for overall effect: Z = 3.59 (P = 0.00033)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
Analysis 1.5. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 5 Loss of 6 or more letters of contrast sensitivity at 24 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 5 Loss of 6 or more letters of contrast sensitivity at 24 months
Study or subgroup PDT Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TAP 1999 86/402 94/207 0.47 [ 0.37, 0.60 ]
VIP 2001 32/161 31/90 0.58 [ 0.38, 0.88 ]
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.6. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 6 Loss of 15 or more letters of contrast sensivitiy at 24 mths.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 6 Loss of 15 or more letters of contrast sensivitiy at 24 mths
Study or subgroup PDT Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TAP 1999 27/402 24/207 0.58 [ 0.34, 0.98 ]
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
Analysis 1.7. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 7 Gain of 3 or more lines (15 or more letters) of visual acuity at 12 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 7 Gain of 3 or more lines (15 or more letters) of visual acuity at 12 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
TAP 1999 24/402 5/207 69.8 % 2.47 [ 0.96, 6.38 ]
VIP 2001 5/166 2/92 23.9 % 1.39 [ 0.27, 7.00 ]
VIM 2005 1/36 0/38 6.3 % 3.16 [ 0.13, 75.20 ]
Total (95% CI) 604 337 100.0 % 2.19 [ 0.99, 4.83 ]
Total events: 30 (PDT), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 1.8. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 8 Gain of 3 or more lines (15 or more letters) of visual acuity at 24 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 8 Gain of 3 or more lines (15 or more letters) of visual acuity at 24 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
TAP 1999 36/402 8/207 80.3 % 2.32 [ 1.10, 4.89 ]
VIP 2001 8/166 1/92 10.5 % 4.43 [ 0.56, 34.90 ]
VIM 2005 3/36 1/38 9.1 % 3.17 [ 0.35, 29.06 ]
Total (95% CI) 604 337 100.0 % 2.55 [ 1.31, 4.99 ]
Total events: 47 (PDT), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0061)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.9. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 9 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 12 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 9 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 12 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No classic CNV
TAP 1999 14/38 13/19 6.0 % 0.54 [ 0.32, 0.90 ]
VIO 2007 66/219 45/111 20.7 % 0.74 [ 0.55, 1.01 ]
VIP 2001 85/166 51/92 22.8 % 0.92 [ 0.73, 1.17 ]
Subtotal (95% CI) 423 222 49.6 % 0.80 [ 0.67, 0.96 ]
Total events: 165 (PDT), 109 (Placebo)
Heterogeneity: Chi2 = 3.91, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Classic CNV > 0% to < 50%
TAP 1999 89/202 46/103 21.2 % 0.99 [ 0.76, 1.29 ]
VIM 2005 10/36 18/38 6.1 % 0.59 [ 0.31, 1.09 ]
Subtotal (95% CI) 238 141 27.2 % 0.90 [ 0.70, 1.14 ]
Total events: 99 (PDT), 64 (Placebo)
Heterogeneity: Chi2 = 2.27, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.87 (P = 0.38)
3 Classic CNV > 50% (predominantly classic)
TAP 1999 52/159 51/84 23.2 % 0.54 [ 0.41, 0.71 ]
Subtotal (95% CI) 159 84 23.2 % 0.54 [ 0.41, 0.71 ]
Total events: 52 (PDT), 51 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.31 (P = 0.000017)
Total (95% CI) 820 447 100.0 % 0.77 [ 0.68, 0.87 ]
Total events: 316 (PDT), 224 (Placebo)
Heterogeneity: Chi2 = 14.45, df = 5 (P = 0.01); I2 =65%
Test for overall effect: Z = 4.10 (P = 0.000041)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.10. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 10 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 24 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 10 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 24 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No classic CNV
TAP 1999 18/41 14/20 5.0 % 0.63 [ 0.40, 0.98 ]
VIO 2007 114/244 63/120 22.4 % 0.89 [ 0.72, 1.11 ]
VIP 2001 91/166 63/92 21.5 % 0.80 [ 0.66, 0.97 ]
Subtotal (95% CI) 451 232 49.0 % 0.82 [ 0.72, 0.95 ]
Total events: 223 (PDT), 140 (Placebo)
Heterogeneity: Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.72 (P = 0.0064)
2 Classic CNV > 0 to < 50%
TAP 1999 106/202 58/104 20.3 % 0.94 [ 0.76, 1.17 ]
VIM 2005 17/32 23/37 5.7 % 0.85 [ 0.57, 1.29 ]
VIP 2001 19/38 10/18 3.6 % 0.90 [ 0.53, 1.52 ]
Subtotal (95% CI) 272 159 29.6 % 0.92 [ 0.77, 1.10 ]
Total events: 142 (PDT), 91 (Placebo)
Heterogeneity: Chi2 = 0.17, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
3 Classic CNV > 50% (predominantly classic)
TAP 1999 65/159 57/83 19.9 % 0.60 [ 0.47, 0.75 ]
VIP 2001 10/16 3/3 1.5 % 0.71 [ 0.42, 1.19 ]
Subtotal (95% CI) 175 86 21.4 % 0.60 [ 0.48, 0.75 ]
Total events: 75 (PDT), 60 (Placebo)
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 4.46 (P < 0.00001)
Total (95% CI) 898 477 100.0 % 0.80 [ 0.73, 0.89 ]
Total events: 440 (PDT), 291 (Placebo)
Heterogeneity: Chi2 = 10.76, df = 7 (P = 0.15); I2 =35%
Test for overall effect: Z = 4.32 (P = 0.000015)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
44Photodynamic therapy for neovascular age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.11. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 11 Adverse effects: acute severe visual acuity decrease.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 11 Adverse effects: acute severe visual acuity decrease
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VIM 2005 1/87 1/40 50.9 % 0.46 [ 0.03, 7.17 ]
TAP 1999 3/402 0/207 24.5 % 3.61 [ 0.19, 69.61 ]
VIP 2001 10/225 0/114 24.6 % 10.69 [ 0.63, 180.74 ]
Total (95% CI) 714 361 100.0 % 3.75 [ 0.87, 16.12 ]
Total events: 14 (PDT), 1 (Placebo)
Heterogeneity: Chi2 = 2.77, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 1.78 (P = 0.076)
0.001 0.01 0.1 1 10 100 1000
Favours PDT Favours placebo
Analysis 1.12. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 12 Adverse effects: visual disturbance.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 12 Adverse effects: visual disturbance
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TAP 1999 89/402 32/207 51.4 % 1.43 [ 0.99, 2.07 ]
VIP 2001 94/225 26/114 42.0 % 1.83 [ 1.26, 2.66 ]
VIM 2005 7/87 4/40 6.7 % 0.80 [ 0.25, 2.59 ]
Total (95% CI) 714 361 100.0 % 1.56 [ 1.21, 2.01 ]
Total events: 190 (PDT), 62 (Placebo)
Heterogeneity: Chi2 = 2.16, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 3.42 (P = 0.00062)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.13. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 13 Adverse effects: injection site.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 13 Adverse effects: injection site
Study or subgroup PDT Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TAP 1999 64/402 12/207 51.4 % 3.08 [ 1.62, 5.84 ]
VIP 2001 18/225 6/114 28.2 % 1.57 [ 0.60, 4.06 ]
VIM 2005 3/87 4/40 20.4 % 0.32 [ 0.07, 1.51 ]
Total (95% CI) 714 361 100.0 % 2.09 [ 1.29, 3.39 ]
Total events: 85 (PDT), 22 (Placebo)
Heterogeneity: Chi2 = 7.38, df = 2 (P = 0.03); I2 =73%
Test for overall effect: Z = 2.98 (P = 0.0029)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.14. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 14 Adverse effects: infusion-related back pain.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 14 Adverse effects: infusion-related back pain
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TAP 1999 10/402 0/207 19.6 % 10.84 [ 0.64, 184.05 ]
VIP 2001 5/225 0/114 19.7 % 5.60 [ 0.31, 100.35 ]
VIM 2005 9/87 1/40 40.8 % 4.14 [ 0.54, 31.56 ]
VIO 2007 25/244 0/120 19.9 % 25.19 [ 1.55, 410.23 ]
Total (95% CI) 958 481 100.0 % 9.93 [ 2.82, 35.02 ]
Total events: 49 (PDT), 1 (Placebo)
Heterogeneity: Chi2 = 1.30, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.57 (P = 0.00036)
0.02 0.1 1 10 50
Favours PDT Favours placebo
Analysis 1.15. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 15 Adverse effects: allergic reactions.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 15 Adverse effects: allergic reactions
Study or subgroup PDT Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TAP 1999 8/402 3/207 49.7 % 1.38 [ 0.36, 5.26 ]
VIP 2001 3/225 3/114 50.3 % 0.50 [ 0.10, 2.52 ]
Total (95% CI) 627 321 100.0 % 0.94 [ 0.34, 2.56 ]
Total events: 11 (PDT), 6 (Placebo)
Heterogeneity: Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.16. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 16 Adverse effects: photosensitivity reactions.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 16 Adverse effects: photosensitivity reactions
Study or subgroup PDT Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TAP 1999 14/402 0/207 32.5 % 15.49 [ 0.92, 260.96 ]
VIP 2001 1/225 1/114 67.5 % 0.50 [ 0.03, 8.14 ]
Total (95% CI) 627 321 100.0 % 5.37 [ 1.01, 28.60 ]
Total events: 15 (PDT), 1 (Placebo)
Heterogeneity: Chi2 = 3.32, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 1.97 (P = 0.049)
0.02 0.1 1 10 50
Favours PDT Favours placebo
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Analysis 1.17. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 17 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 12 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 17 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 12 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No classic CNV
VIO 2007 66/219 45/111 41.8 % 0.74 [ 0.55, 1.01 ]
VIP 2001 85/166 51/92 45.9 % 0.92 [ 0.73, 1.17 ]
Subtotal (95% CI) 385 203 87.7 % 0.84 [ 0.69, 1.01 ]
Total events: 151 (PDT), 96 (Placebo)
Heterogeneity: Chi2 = 1.26, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 1.85 (P = 0.065)
2 Classic CNV > 0% to < 50%
VIM 2005 10/36 18/38 12.3 % 0.59 [ 0.31, 1.09 ]
Subtotal (95% CI) 36 38 12.3 % 0.59 [ 0.31, 1.09 ]
Total events: 10 (PDT), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
3 Classic CNV > 50% (predominantly classic)
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (PDT), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 421 241 100.0 % 0.81 [ 0.67, 0.97 ]
Total events: 161 (PDT), 114 (Placebo)
Heterogeneity: Chi2 = 2.55, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.33 (P = 0.020)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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Analysis 1.18. Comparison 1 PHOTODYNAMIC THERAPYWITH VERTEPORFIN VERSUS PLACEBO,
Outcome 18 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 24 months.
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 18 Subgroup analysis: lesion area composed of classic CNV. Loss of 3 or more lines at 24 months
Study or subgroup PDT Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No classic CNV
VIO 2007 114/244 63/120 41.0 % 0.89 [ 0.72, 1.11 ]
VIP 2001 91/166 63/92 39.3 % 0.80 [ 0.66, 0.97 ]
Subtotal (95% CI) 410 212 80.3 % 0.85 [ 0.73, 0.98 ]
Total events: 205 (PDT), 126 (Placebo)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
2 Classic CNV > 0 to < 50%
VIM 2005 17/32 23/37 10.4 % 0.85 [ 0.57, 1.29 ]
VIP 2001 19/38 10/18 6.6 % 0.90 [ 0.53, 1.52 ]
Subtotal (95% CI) 70 55 16.9 % 0.87 [ 0.63, 1.20 ]
Total events: 36 (PDT), 33 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
3 Classic CNV > 50% (predominantly classic)
VIP 2001 10/16 3/3 2.7 % 0.71 [ 0.42, 1.19 ]
Subtotal (95% CI) 16 3 2.7 % 0.71 [ 0.42, 1.19 ]
Total events: 10 (PDT), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 496 270 100.0 % 0.85 [ 0.74, 0.97 ]
Total events: 251 (PDT), 162 (Placebo)
Heterogeneity: Chi2 = 1.03, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
0.1 0.2 0.5 1 2 5 10
Favours PDT Favours placebo
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A D D I T I O N A L T A B L E S
Table 1. Summary of reports of the TAP and VIP trials
Title Year Content
TAP 1 1999 12 month outcomes
TAP 2 2001 24 month outcomes
TAP 3 2002 Baseline lesion type subgroup analysis
TAP 4 2002 Contrast sensitivity outcomes
TAP 5 2002 Open label 36 month outcomes
TAP 6 2004 Natural history of minimally classic lesions
TAP 7 2005 48 month open label outcomes
TAP 8 2006 60 month open label outcomes
TAP & VIP 1 2003 Effect of baseline lesion characteristics and vision on outcome
TAP & VIP 2 2003 Fluorescein angiography guidelines for grading lesions and repeatability
TAP & VIP 3 2004 Acute Severe Visual Acuity Decrease
VIP 1 2001 12 month outcomes for neovascular membranes due to pathologic myopia
VIP 2 2001 24 month outcomes occult no classic lesions
VIP 3 2003 24 month outcomes for neovascular membranes due to pathologic myopia
VIP 4 2006 Natural history of large occult lesions
Table 2. Outcome reporting grid
TAP 1999 VIP 2001 VIM 2005 VIO 2007
3+ lines 12 mths
√ √ √ √
3+ lines 24 mths
√ √ √ √
6+lines 12 mths
√ √
(subgroup only)
√ √
6+ lines 24 mths
√ √ √ √
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Table 2. Outcome reporting grid (Continued)
Final mean VA 12 mths Mean value reported but
no measures of variabil-
ity
√
(subgroup only) Median value only re-
ported
√
Final mean VA 24 mths Mean value reported but
no measures of variabil-
ity
√
(subgroup only) Median value only re-
ported
√
Change in VA 12 mths Mean value reported but
no measures of variabil-
ity
√
(subgroup only) Mean change reported in
graph but nomeasures of
variability
√
Change in VA 24 mths Mean value reported but
no measures of variabil-
ity
√
(subgroup only) Mean change reported in
graph but nomeasures of
variability
√
Contrast sensitivity 12
mths
√
Outcome probably mea-
sured but not clear if
analysed
Not reported; unclear if
data collected
Not reported; unclear if
data collected
Contrast sensitivity 24
mths
√ √
(subgroup only) Not reported; unclear if
data collected
Not reported; unclear if
data collected
New vessel growth 12
mths
√
“Angiographic progres-
sion to predominantly
classic CNV”
Clear that angiographic
outcomes analysed but
only reported as not sig-
nificant
New vessel growth 24
mths
√
“Angiographic progres-
sion to predominantly
classic CNV”
Clear that angiographic
outcomes analysed but
only reported as not sig-
nificant
Quality of life QOL study mentioned
in protocol but no data
reported
Not reported; unclear if
data collected
Not reported; unclear if
data collected
Adverse outcomes
Visual disturbance
√ √ √
Not reported
Vitreous haemorrhage
√
Not reported Not reported Not reported
Retinal capillary nonper-
fusion
√
Not reported Not reported Not reported
Injection site adverse
event
√ √ √
Not reported
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Table 2. Outcome reporting grid (Continued)
Infusion-related back
pain
√ √ √ √
Allergic reactions
√ √ √
Not reported
Photosensitivity
reactions
√ √ √
Not reported
Severe vision decrease
within 7 days
√ √ √
Not reported
Deaths Not reported Not reported
√ √
Retinal vascular occlu-
sive events
Not reported Not reported
√
Not reported
Subretinal/intraretinal
haemorrhage
Not reported Not reported
√
Not reported
Discontinuation Not reported Not reported Not reported
√
Table 3. Mean change in visual acuity
Number of let-
ters visual acuity
lost
12 months 24 months
PDT Placebo Difference PDT Placebo Difference
TAP 1999* 11 17.5 6.5 13.4 19.6 6.2
VIP 2001 15.6 20.8 5.2 19 25.5 6.5
VIM 2005** 9 13.5 4.5 16 21 5
VIO 2007*** 11.2 13.3 2.1 14.8 17.8 3
*calculated from reported number of lines lost
** median score: reported test of difference between 2 groups: P (12 months) =0.36; p(24 months) = 0.12
*** reported test of difference between 2 groups: P (12 months) =0.26; p(24 months) = 0.14
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Table 4. Final visual acuity score
Number of let-
ters visual acuity
12 months 24 months
PDT Placebo Difference PDT Placebo Difference
TAP 1999 42 35 7 39.4 32.9 6.5
VIP 2001 50 44 6 47 40 7
VIM 2005 49 39 10 41.5 36 -5.5
VIO 2007 45.9 42.4 3.5* 42.3 37.8 4.5**
*P = 0.11 (2 tailed ttest calculated from data reported: PDT group SD=19.8, placebo group SD=18.3).
**P = 0.05. (2 tailed ttest calculated from data reported: PDT group SD=20.8, placebo group SD=18.0).
Table 5. Lesion area composed of classic CNV
Lesion area composed of
classic CNV
50% or more
“predominantly classic”
Some classic CNV but
less than 50%
No classic CNV (occult
only)
Unclear
TAP 1999 40% 50% 9% 1%
VIP 2001 6% 17% 68% 10%
VIM 2005 0% 78% 13% 9%
VIO 2007 No data provided however patients enrolled in the trial had to have “occult CNV with evidence of disease
progression”
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 ((macul* OR retina* OR choroid*) AND (degener* OR neovasc*))
#6 maculopath*
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8 MeSH descriptor Photochemotherapy
#9 MeSH descriptor Photosensitizing Agents
#10 photodynamic* or PDT or photosensit*
#11 MeSH descriptor Porphyrins
#12 verteporfin* or visudyne*
#13 benzoporphyrin* or porphyrin*
#14 (#8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 (#7 AND #14)
Appendix 2. MEDLINE search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. maculopath$.tw.
18. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
19. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
20. or/13-19
21. exp photochemotherapy/
22. exp photosensitizing agents/
23. (photodynamic$ or PDT or photosensit$).tw.
24. exp porphyrins/
25. (verteporfin$ or visudyne$).tw.
26. (benzoporphyrin$ or porphyrin$).tw.
27. or/21-26
28. 20 and 27
29. 12 and 28
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
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Appendix 3. EMBASE search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula age related degeneration/
34. exp retina macula degeneration/
35. exp retina degeneration/
36. exp subretinal neovascularization/
37. exp neovascularization pathology/
38. maculopath$.tw.
39. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
40. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
41. or/33-40
42. exp photodynamic therapy/
43. exp photosensitizing agent/
44. (photodynamic$ or PDT or photosensit$).tw.
45. exp porphyrin/
46. (verteporfin$ or visudyne$).tw.
47. (benzoporphyrin$ or porphyrin$).tw.
48. or/42-47
49. 41 and 48
50. 32 and 49
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Appendix 4. Results of searches for previous versions of this review
The original electronic searches identified 76 reports. We found one randomised controlled trial (TAP 1999). Since the searches were
updated in February 2001, May 2002 and January 2003 one further study was identified and included in the review (VIP 2001).
A further search update was conducted in January 2005. A total of 284 new reports were found. No reports of new trials were found
though there were a number of new reports from existing trials including new outcomes on contrast sensitivity (Rubin 2002), central
visual field function (Schmidt-Erfurth 2004) and subretinal neovascular morphology (Schmidt-Erfurth 2003). In addition we found
one systematic review (Meads 2004), a meta-analysis of safety results in TAP and VIP (Azab 2004) and a cost-utility analysis (Hopley
2004). A report on severe visual acuity decrease in TAP and VIP (Arnold 2004) was also considered relevant. An outcome study
reporting visual function and related quality of life was found (Armbrecht 2004). A number of papers from the TAP and VIP studies
were found including guidelines for evaluation of fluorescein angiographic findings and treatment (Barbazetto 2003), determinants of
outcome according to lesion size, visual acuity and lesion composition (Blinder 2003), baseline lesion composition’s impact on vision
outcome (Bressler 2002) and natural history of minimally classic lesions (Bressler 2004a).
We found one traditional review of PDT (Woodburn 2002) mentions trials on other agents, such as etiopurpurin (Purlytin) and
motexafin lutetium (Optrin) undergoing phase III and phase II trials respectively.
The search conducted in March 2007 revealed the findings of one new trial - the verteporfin therapy of subfoveal minimally classic
choroidal neovascularisation in age-related macular degeneration trial which was previously in the ongoing studies list (VIM 2005).
The search found 446 new references and found reports of some of the other studies in abstract form only. (see details of ongoing
studies). The VIM 2005 study appeared relevant and worthy of inclusion.
WH A T ’ S N E W
Last assessed as up-to-date: 22 April 2009.
Date Event Description
12 August 2009 New search has been performed Issue 4, 2009: Updated searches yielded one new trial.
H I S T O R Y
Review first published: Issue 2, 2000
Date Event Description
17 September 2008 Amended Converted to new review format.
22 May 2007 New citation required and conclusions have changed Substantive amendment. One new trial (VIM 2005)
has been added
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C O N T R I B U T I O N S O F A U T H O R S
RW participated in protocol development, study selection and assessment and writing up of the original and update of the review.
JE participated in protocol development, study selection and assessment, data abstraction and entry and writing up of the original and
update of the review.
LS participated in protocol development, study selection and assessment, data abstraction and entry and writing up of the original and
update of the review.
KH abstracted data and entered data into RevMan for the update of the review and participated in the updating of the review text.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Moorfields Eye Hospital NHS Trust, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added in a new outcome “gain of 3+ lines of visual acuity”.
We have assessed risk of bias using the new Cochrane Collaboration’s tool for assessing the risk of bias.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Photochemotherapy; Glucose [therapeutic use]; Macular Degeneration [complications; ∗drug therapy]; Photosensitizing Agents
[∗therapeutic use]; Porphyrins [∗therapeutic use]; Randomized Controlled Trials as Topic; Retinal Neovascularization [∗drug therapy]
MeSH check words
Humans
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